Nature Search

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial

The final analysis from the phase 3 IMpassion031 trial shows that adding atezolizumab to chemotherapy for stage II/III triple-negative breast cancer is associated with favorable long-term outcomes, with circulating tumor DNA clearance correlating with therapy response.

Elizabeth A. Mittendorf
Zoe June Assaf
Carlos H. Barrios
ResearchOpen Access04 Jun 2025
Nature Medicine

Volume: 31, P: 2397-2404
Sacituzumab govitecan in HR⁺HER2⁻ metastatic breast cancer: the randomized phase 3 EVER-132-002 trial

In the phase 3 EVER-132-002 trial, patients with HR⁺HER2⁻ metastatic breast cancer from Asia were treated with the Trop-2-directed antibody–drug conjugate sacituzumab govitecan or chemotherapy, and those receiving sacituzumab govitecan experienced prolonged progression-free survival compared with patients treated with chemotherapy.

Binghe Xu
Shusen Wang
Ming-Shen Dai
ResearchOpen Access01 Oct 2024
Nature Medicine

Volume: 30, P: 3709-3716
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)

Sung Hoon Sim
In Hae Park
Jungsil Ro
ResearchOpen Access06 Nov 2019
British Journal of Cancer

Volume: 121, P: 985-990
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

Emi Noguchi
Takashi Yamanaka
Kan Yonemori
ResearchOpen Access22 Aug 2024
npj Breast Cancer

Volume: 10, P: 1-10
GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8⁺/CD4⁺ T cells and TILs in patients with locally advanced or metastatic solid tumours

Gun Min Kim
Sojeong Kim
Joohyuk Sohn
ResearchOpen Access09 Jun 2025
British Journal of Cancer

Volume: 133, P: 524-532
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Stephen Johnston
Joyce O’Shaughnessy
Matthew P. Goetz
ResearchOpen Access22 Jun 2021
npj Breast Cancer

Volume: 7, P: 1-5
Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation

Sanghyun Park
Won-Ji Ryu
Joon Kim
ResearchOpen Access16 Apr 2024
Experimental & Molecular Medicine

Volume: 56, P: 987-1000
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer

Howard A. Burris
Arlene Chan
Denise A. Yardley
Research22 Jun 2021
British Journal of Cancer

Volume: 125, P: 679-686
Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy

Hye Yoon Park
Hyeongrae Lee
Eun Lee
ResearchOpen Access08 Jun 2021
Scientific Reports

Volume: 11, P: 1-9
Genomic landscape of extraordinary responses in metastatic breast cancer

Lim, Kim and Jung et al. report a whole-exome sequence analysis of 30 Korean patients showing extreme treatment responses for metastatic breast cancer. They find that compared to non-responders, extreme responders have fewer nonsynonymous mutations and copy number variants.

Sun Min Lim
Eunyoung Kim
Joohyuk Sohn
ResearchOpen Access09 Apr 2021
Communications Biology

Volume: 4, P: 1-9

Search

Filter By:

Search

Quick links